Physician profile
Alexander Blank
NPI 1356961015
$15,387.39
in general payments reported to CMS, 2019-2025
28 companies · $9,039 in 2025
The $9,039 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $192 · 2022: $887 · 2023: $3,031 · 2024: $2,239 · 2025: $9,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,869 · Consulting Fee: $3,897 · Travel and Lodging: $1,196 · Education: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,868.95 |
| Consulting Fee | $3,897.00 |
| Travel and Lodging | $1,196.39 |
| Education | $346.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $4,756.22 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $2,492.47 | 2023-2025 | Tremfya |
| Abbvie INC. | $1,462.06 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $1,168.80 | 2022-2025 | Ilumya, Blu-U, Odomzo |
| Genzyme Corporation | $1,070.33 | 2023-2025 | |
| Dermavant Sciences, INC. | $946.37 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $661.35 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $446.97 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $336.07 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $224.49 | 2023-2025 | Cabtreo, Siliq, Arazlo |
| Botanix Sb INC | $221.64 | 2025 | Sofdra |
| Leo Pharma INC. | $210.08 | 2022-2025 | Adbry |
| Galderma Laboratories, L.P. | $196.40 | 2024-2025 | Nemluvio, Aklief |
| Organon LLC | $192.62 | 2025 | Vtama |
| Janssen Pharmaceuticals, INC | $175.17 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $150.14 | 2023 | Puraply |
| Ucb, INC. | $134.75 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $101.82 | 2022-2024 | |
| Bausch Health US, LLC | $100.85 | 2023 | Siliq, Targretin |
| Mayne Pharma Commercial LLC | $75.43 | 2022-2023 | |
| Amgen INC. | $58.66 | 2024-2025 | Otezla, Otezla |
| Pfizer INC. | $41.33 | 2023 | |
| Incyte Corporation | $40.14 | 2022-2023 | Opzelura |
| Epi Health, LLC | $37.55 | 2022 | |
| Almirall LLC | $24.81 | 2022 | |
| Janssen Scientific Affairs, LLC | $24.42 | 2024 | Tremfya |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.75 | 2021 | |
| Medtronic, INC. | $16.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Blank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.